Phaseline

Targets › IL-18R1

IL-18R1: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Immunology; next expected readout Nov 2026.

Open in Phaseline: the race on IL-18R1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Tulisokibart (MK-7240/PRA023)
IL-18 receptor antagonist
IL-18R1Phase 2Diffuse Cutaneous Systemic SclerosisNov 2026

Conditions

Diffuse Cutaneous Systemic Sclerosis (1)

Modalities

antibody (1)

Companies

Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.